Villemagne, Victor L.

Chronic stress and Alzheimer's disease: the interplay between the hypothalamic–pituitary–adrenal axis, genetics and microglia

Milligan Armstrong, A., Porter, T., Quek, H., White, A., Haynes, J., Jackaman, C., Villemagne, V., Munyard, K., Laws, S. M., Verdile, G., et al. (2021) · Biological Reviews

Stress Responses and CortisolNeuroinflammation and Neurodegeneration Mechanisms

Cited by 116

Aβ-amyloid and Tau Imaging in Dementia

Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 110

Effect of BDNF Val66Met on Memory Decline and Hippocampal Atrophy in Prodromal Alzheimer’s Disease: A Preliminary Study

Lim, Y. Y., Villemagne, V. L., Laws, S. M., Ames, D., Pietrzak, R. H., Ellis, K. A., Harrington, K., Bourgeat, P., Bush, A. I., Martins, R. N., et al. (2014) · PLoS ONE

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 110

Localization of serotonin 5‐HT2 receptors in living human brain by positron emission tomography using N1‐([11C]‐methyl)‐2‐BR‐LSD

Wong, D. F., Lever, J. R., Hartig, P. R., Dannals, R. F., Villemagne, V., Hoffman, B. J., Wilson, A. A., Ravert, H. T., Links, J. M., Scheffel, U., et al. (1987) · Synapse

Neurotransmitter Receptor Influence on BehaviorRadiopharmaceutical Chemistry and Applications

Cited by 94

Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease

Dhiman, K., Gupta, V. B., Villemagne, V. L., Eratne, D., Graham, P. L., Fowler, C., Bourgeat, P., Li, Q., Collins, S., Bush, A. I., et al. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 93

Comparison of 18F‐florbetaben quantification results using the standard Centiloid, MR‐based, and MR‐less CapAIBL® approaches: Validation against histopathology

Doré, V., Bullich, S., Rowe, C. C., Bourgeat, P., Konate, S., Sabri, O., Stephens, A. W., Barthel, H., Fripp, J., Masters, C. L., et al. (2019) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 93

Tau imaging with [18F]THK‐5351 in progressive supranuclear palsy

Ishiki, A., Harada, R., Okamura, N., Tomita, N., Rowe, C. C., Villemagne, V. L., Yanai, K., Kudo, Y., Arai, H., Furumoto, S., et al. (2017) · European Journal of Neurology

Alzheimer's disease research and treatmentsParkinson's Disease Mechanisms and Treatments

Cited by 92

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease

Mattsson, N., Groot, C., Jansen, W. J., Landau, S. M., Villemagne, V. L., Engelborghs, S., Mintun, M. M., Lleo, A., Molinuevo, J. L., Jagust, W. J., et al. (2018) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 88

APOE ε4 associates with microglial activation independently of Aβ plaques and tau tangles

Ferrari-Souza, J. P., Lussier, F. Z., Leffa, D. T., Therriault, J., Tissot, C., Bellaver, B., Ferreira, P. C. L., Malpetti, M., Wang, Y.-T., Povala, G., et al. (2023) · Science Advances

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 81

Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer’s disease

Chételat, G., Ossenkoppele, R., Villemagne, V. L., Perrotin, A., Landeau, B., Mézenge, F., Jagust, W. J., Dore, V., Miller, B. L., Egret, S., et al. (2016) · Brain

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 80

Appearance modeling of 11C PiB PET images: Characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging

Fripp, J., Bourgeat, P., Acosta, O., Raniga, P., Modat, M., Pike, K. E., Jones, G., O'Keefe, G., Masters, C. L., Ames, D., et al. (2008) · NeuroImage

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 80

Early detection of amyloid load using 18F-florbetaben PET

Bullich, S., Roé-Vellvé, N., Marquié, M., Landau, S. M., Barthel, H., Villemagne, V. L., Sanabria, Á., Tartari, J. P., Sotolongo-Grau, O., Doré, V., et al. (2021) · Alzheimer's Research & Therapy

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 71

Synthesis of an I-123 analog of A-85380 and preliminary SPECT imaging of nicotinic receptors in baboon

Musachio, J. L., Villemagne, V. L., Scheffel, U. A., Dannals, R. F., Dogan, A. S., Yokoi, F., & Wong, D. F. (1999) · Nuclear Medicine and Biology

Radiopharmaceutical Chemistry and ApplicationsNicotinic Acetylcholine Receptors Study

Cited by 67

Amyloid-β Related Memory Decline is not Associated with Subjective or Informant Rated Cognitive Impairment in Healthy Adults

Hollands, S., for the AIBL Research Group, Lim, Y. Y., Buckley, R., Pietrzak, R. H., Snyder, P. J., Ames, D., Ellis, K. A., Harrington, K., Lautenschlager, N., et al. (2014) · Journal of Alzheimer's Disease

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 67

Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer’s Disease: Results from the DIAN Study Group

Su, Y., Blazey, T. M., Owen, C. J., Christensen, J. J., Friedrichsen, K., Joseph-Mathurin, N., Wang, Q., Hornbeck, R. C., Ances, B. M., Snyder, A. Z., et al. (2016) · PLOS ONE

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 56

Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden

Rembach, A., the AIBL Research Group, Watt, A. D., Wilson, W. J., Villemagne, V. L., Burnham, S. C., Ellis, K. A., Maruff, P., Ames, D., Rowe, C. C., et al. (2014) · Journal of Alzheimer's Disease

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 48

Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes

Tan, R. H., Kril, J. J., Yang, Y., Tom, N., Hodges, J. R., Villemagne, V. L., Rowe, C. C., Leyton, C. E., Kwok, J. B. J., Ittner, L. M., et al. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 48

APOEε4 potentiates amyloid β effects on longitudinal tau pathology

Ferrari-Souza, J. P., Bellaver, B., Ferreira, P. C. L., Benedet, A. L., Povala, G., Lussier, F. Z., Leffa, D. T., Therriault, J., Tissot, C., Soares, C., et al. (2023) · Nature Aging

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 43

β-Amyloid, APOE and BDNF Genotype, and Depressive and Anxiety Symptoms in Cognitively Normal Older Women and Men

Holmes, S. E., Esterlis, I., Mazure, C. M., Lim, Y. Y., Ames, D., Rainey-Smith, S., Martins, R. N., Salvado, O., Dore, V., Villemagne, V. L., et al. (2016) · The American Journal of Geriatric Psychiatry

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 40

The ADNI PET core at 20

Jagust, W. J., Koeppe, R. A., Rabinovici, G. D., Villemagne, V. L., Harrison, T. M., Landau, S. M., & Initiative, T. A. D. N. (2024) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 34

Relationship between amyloid-β positivity and progression to mild cognitive impairment or dementia over 8 years in cognitively normal older adults

Dang, C., Harrington, K. D., Lim, Y. Y., Ames, D., Hassenstab, J., Laws, S. M., Yassi, N., Hickey, M., Rainey-Smith, S., Robertson, J., et al. (2018) · Journal of Alzheimer’s Disease

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 31

Multicenter 18F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer’s Disease

Rullmann, M., Brendel, M., Schroeter, M. L., Saur, D., Levin, J., Perneczky, R. G., Tiepolt, S., Patt, M., Mueller, A., Villemagne, V. L., et al. (2022) · Biomolecules

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 29

Validation of a priori candidate Alzheimer’s disease SNPs with brain amyloid-beta deposition

Vacher, M., Porter, T., Villemagne, V. L., Milicic, L., Peretti, M., Fowler, C., Martins, R., Rainey-Smith, S., Ames, D., Masters, C. L., et al. (2019) · Scientific Reports

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 26

Towards cascading genetic risk in Alzheimer’s disease

Altmann, A., Aksman, L. M., Oxtoby, N. P., Young, A. L., ADNI, Weiner, M., Aisen, P., Petersen, R., Weiner, M., Aisen, P., et al. (2024) · Brain

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 18